M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
NCT ID: NCT03631706
Last Updated: 2025-04-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
304 participants
INTERVENTIONAL
2018-10-01
2024-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
NCT03664024
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
NCT03976362
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02220894
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976323
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
M7824
M7824
Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Pembrolizumab
Pembrolizumab
Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
M7824
Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Pembrolizumab
Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have not received prior systemic therapy treatment for their advanced/Stage four NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy to Grade less than or equal to 1. For radiation toxicity or prior major surgeries, participants should have recovered from side effects and/or complications
* Have measurable disease based on RECIST 1.1
* Have a life expectancy of at least 3 months
* Availability of tumor tissue (less than 6 months old) before the first dose is mandatory to determine PD-L1 expression level prior to enrollment
* PD-L1 high status as determined by central testing
Exclusion Criteria
* Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy of greater than 30 units of gray (Gy) within 6 months prior to the first dose of study
* Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or any components in their formulations
* Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncology Specialties, PC; Clearview Cancer Institute
Huntsville, Alabama, United States
Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic
Los Angeles, California, United States
UC Irvine Medical Center
Orange, California, United States
Kaiser Permanente - Harbor City
San Diego, California, United States
Sansum Clinic - Santa Barbara
Santa Barbara, California, United States
Rocky Mountain Cancer Centers - Colorado Springs, N. Nevada
Colorado Springs, Colorado, United States
Eastern Connecticut Hematology/Oncology Assoc.
Norwich, Connecticut, United States
Cancer Specialists, LLC - Department of Clinical Research
Jacksonville, Florida, United States
Woodlands Medical Specialists
Pensacola, Florida, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Decatur Memorial Hospital - Clinical Research
Decatur, Illinois, United States
Baptist Health Lexington Oncology Associates
Lexington, Kentucky, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Henry Ford Medical Center
Detroit, Michigan, United States
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC - Menorah Medical Center - Oncology Account
Kansas City, Missouri, United States
Southeast Nebraska Cancer Center
Lincoln, Nebraska, United States
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey, United States
University of Rochester Medical Center
Rochester, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
UPMC Cancer Center
Pittsburgh, Pennsylvania, United States
SCRI - Tennessee Oncology
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Texas Oncology - Bedford
Bedford, Texas, United States
Texas Oncology, P.A. - Sugarland
Sugar Land, Texas, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Centro de Oncologia e Investigacion Buenos Aires
Berazategui, , Argentina
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma Buenos Aires, , Argentina
Sanatorio Allende
Córdoba, , Argentina
Instituto Medico Rio Cuarto
Río Cuarto, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
Centro Medico San Roque S.R.L.
San Miguel de Tucumán, , Argentina
Universitair Ziekenhuis Brussel - Geriatrie
Brussels, , Belgium
Jessa Ziekenhuis Hospital
Hasselt, , Belgium
UZ Leuven
Pellenberg, , Belgium
CHU Mont-Godinne
Yvoir, , Belgium
Hospital de Câncer de Barretos - Fundação Pio XII
Barretos, , Brazil
CRIO - Centro Regional Integrado de Oncologia
Fortaleza, , Brazil
Hospital São Lucas da PUCRS
Porto Alegre, , Brazil
INCA - Instituto Nacional de Câncer
Rio de Janeiro, , Brazil
NOB - Núcleo de Oncologia da Bahia
Salvador, , Brazil
CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia - Faculdade de Medicina do ABC
Santo André, , Brazil
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Tom Baker Cancer Centre
Alberta, , Canada
Stronach Regional Cancer Centre - at Southlake
Ontario, , Canada
Peking University Cancer Hospital
Beijing, , China
Guangdong General Hospital
Guangzhou, , China
Shanghai Cancer Hospital, Fudan University
Shanghai, , China
Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Ha
Pessac, Gironde, France
Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie
Créteil, Val De Marne, France
Hôpital Nord - AP-HM Marseille# - Service d'Oncologie Multidisciplinaire
Bouches-du-Rhône, , France
Centre Léon Bérard
Lyon, , France
CHU Rennes - Hopital Pontchaillou - service de pneumologie
Rennes, , France
ICO - Site René Gauducheau
Saint-Herblain, , France
CHU de Toulouse - Hôpital Larrey - Service de Pneumologie et Oncologie Pneumologique
Toulouse, , France
Vivantes Klinikum Am Urban - Haematologie und Onkologie
Berlin, , Germany
Asklepios Fachkliniken Muenchen-Gauting - Abteilung Internistische Onkologie
Gauting, , Germany
LungenClinic Grosshansdorf
Großhansdorf, , Germany
Medizinische Hochschule Hannover - Pneumologie
Hanover, , Germany
Universitaetsklinikum Schleswig- Holstein Campus Luebeck
Lübeck, , Germany
Universitaetsklinikum Regensburg - Klinik und Poliklinik fuer Innere Medizin II
Regensburg, , Germany
251 General Air Force Hospital
Athens, , Greece
General Hospital of Athens of Chest Disease "SOTIRIA"
Athens, , Greece
University General Hospital of Heraklion "PAGNI"
Heraklion, , Greece
General Hospital Papageorgiou-2nd Department of Dermatalogy
Thessaloniki, , Greece
Princess Margaret Hospital
Hong Kong, , Hong Kong
The University of Hong Kong
Hong Kong, , Hong Kong
The Chinese University of Hong Kong - Emergency Medicine
Shatin, , Hong Kong
Azienda Ospedaliera San Giuseppe Moscati - U.O Oncologia Medica
Avellino, , Italy
IRCCS Centro di Riferimento Oncologico - Oncologia Medica A
Aviano, , Italy
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Oncologia Medica
Bologna, , Italy
Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico - Unità Operativa di Oncologia
Catania, , Italy
Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario - Centro Oncologico
Catanzaro, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori - Medicina Oncologica I
Milan, , Italy
Università degli studi della Campania Luigi Vanvitelli - Dipartimento di Oncologia
Napoli, , Italy
NHO Hokkaido Cancer Center - Dept of Respiratory Medicine
Sapporo, Hokkaido, Japan
National Cancer Center Hospital - Dept of Respiratory Medicine
Chūōku, , Japan
Saitama Medical University International Medical Center - Dept of Respiratory Medicine
Hidaka-shi, , Japan
Saitama Cancer Center
Kitaadachigun, , Japan
Cancer Institute Hospital of JFCR - Dept of Respiratory Medicine
Kōtoku, , Japan
Kurume University Hospital
Kurume-shi, , Japan
Osaka Medical Center for Cancer and Cardiovascular Diseases
Osaka, , Japan
Kindai University Hospital
Osakasayama-sh, , Japan
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, , Netherlands
VU Medisch Centrum
Amsterdam, , Netherlands
Universitair Medisch Centrum Groningen (UMCG) - Parent
Groningen, , Netherlands
Maastricht University Medical Center - Dept of Medical Oncology
Maastricht, , Netherlands
Erasmus Medisch Centrum
Rotterdam, , Netherlands
St. Elisabeth Ziekenhuis - Parent
Tilburg, , Netherlands
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Hospital del Mar - Servicio de Oncologia
Barcelona, , Spain
Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica
Barcelona, , Spain
Hospital Universitari Vall d'Hebron - Dept of Oncology
Barcelona, , Spain
ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia
L'Hospitalet de Llobregat, , Spain
Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica
Madrid, , Spain
Hospital Universitario 12 de Octubre - Servicio de Oncologia
Madrid, , Spain
Hospital Regional Universitario de Malaga
Málaga, , Spain
Hospital Universitario Virgen Macarena - Servicio de Oncologia
Seville, , Spain
Hospital Universitario Virgen del Rocio - Servicio de Oncologia
Seville, , Spain
Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica
Valencia, , Spain
Taichung Veterans General Hospital
Taichung, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Tri-Service General Hospital
Taipei, , Taiwan
Adana Numune Training and Research Hospital - Cardiology Department
Adana, , Turkey (Türkiye)
Dr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital - Oncology Department
Ankara, , Turkey (Türkiye)
Trakya University Medical Faculty - Medical Oncology
Edirne, , Turkey (Türkiye)
Kocaeli University Research and Application Hospital
Kocaeli, , Turkey (Türkiye)
CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU - Ch of Oncology and MR
Dnipro, , Ukraine
CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU - Chair of Oncology
Ivano-Frankivsk, , Ukraine
Communal Non-profit Enterprise Regional Center of Oncology - Parent
Kharkiv, , Ukraine
Medical and Preventive Treatment Institution Volyn Regional Oncological Dispensary - Dept of Oncochemotherapy
Lutsk, , Ukraine
CCCH City Oncological Center SHEI Uzhgorod NU - Ch of R&O of Faculty of PGE&PUT
Uzhhorod, , Ukraine
Medical center "Oncolife"
Zaporizhzhia, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 Dec;18(12):1731-1742. doi: 10.1016/j.jtho.2023.08.018. Epub 2023 Aug 18.
Milenkovic-Grisic AM, Terranova N, Mould DR, Vugmeyster Y, Mrowiec T, Machl A, Girard P, Venkatakrishnan K, Khandelwal A. Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trials. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):143-153. doi: 10.1002/psp4.13068. Epub 2023 Dec 13.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
US Medical Information website, Medical Resources
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-001517-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MS200647_0037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.